TRAIL Protein (AA 95-281, Extracellular Domain, Soluble)

N° du produit ABIN1344417

Détail du produit

Antigène: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Type de proteíne: Recombinant

Activité biologique: Active

Attributs du protein: AA 95-281, Extracellular Domain, Soluble

Origine: Humain

Source: Escherichia coli (E. coli)

Application: SDS-PAGE (SDS)

Specificité: Binds to human TRAIL receptors 1-4 (TRAIL-R1 to TRAIL-R4), izTRAIL does not interact with the apoptosis-inducing mouse TRAIL receptor (TRAIL-R).

Réactivité croisée: Humain

Attributs du produit: The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to an isoleucine zipper motif.

Pureté: >95 % (SDS-PAGE)

niveau d'endotoxine: <0.01EU/μg purified protein (LAL test, Lonza).

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Induces apoptosis in vitro in different human cancer cell lines with an EC50 of 5-200ng/ml, depending on the individual cell line used. Recombinant izTRAIL does not kill 4-day cultures of primary human hepatocytes (PHH) at concentrations of at least up to 1μg/ml (Ganten 2006). Good bioavailability in vivo, shows no toxic effects in mice at doses of at least up to 500μg per day (Wissink 2006).

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized. Contains 20 mM TRIS-Cl, 0.5M arginine-HCl, 100 mM NaCl, 0.02 % Tween 20.

Stock: 4 °C,-20 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C.

Date de péremption: 6 months

Référence

Koschny, Ganten, Sykora, Haas, Sprick, Kolb, Stremmel, Walczak: "TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window." dans: Hepatology (Baltimore, Md.), Vol. 45, Issue 3, pp. 649-58, (2007) (PubMed).

Ganten, Koschny, Sykora, Schulze-Bergkamen, Büchler, Haas, Schader, Untergasser, Stremmel, Walczak: "Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 8, pp. 2640-6, (2006) (PubMed).

Wissink, Verbrugge, Vink, Schader, Schaefer, Walczak, Borst, Verheij: "TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy." dans: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 80, Issue 2, pp. 214-22, (2006) (PubMed).

Détail du antigène

Antigène: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Abstract: TNFSF10 Produits

Synonymes: APO2L Protein, Apo-2L Protein, CD253 Protein, TL2 Protein, TRAIL Protein, A330042I21Rik Protein, AI448571 Protein, APO-2L Protein, Ly81 Protein, Trail Protein, tl2 Protein, apo2l Protein, cd253 Protein, trail Protein, apo-2l Protein, trail1 Protein, xtrail1 Protein, tnfsf10l2 Protein, zgc:92320 Protein, TNLG6A Protein, TNF superfamily member 10 Protein, tumor necrosis factor (ligand) superfamily, member 10 Protein, tumor necrosis factor superfamily member 10 Protein, TNF superfamily member 10 S homeolog Protein, TNFSF10 Protein, Tnfsf10 Protein, tnfsf10.S Protein, tnfsf10 Protein

Sujet: IzTRAIL is a newly available, highly active recombinant form of soluble human TRAIL. Due to a trimerizing N-terminal isoleucine zipper (iz) motif the intrinsic trimerization of TRAIL, required for apoptosis-inducing activity of TRAIL, is enhanced when compared to non-tagged soluble human TRAIL (shTRAIL). Therefore, izTRAIL is a potent inducer of apoptosis in many human cancer cells, but not normal human hepatocytes. In addition, the half-life of izTRAIL is about eight-fold higher than the half-life of shTRAIL. These properties render izTRAIL highly suitable for both, in vitro and in vivo use, particularly for studies in which investigators plan to transfer their in vitro results into an in vivo system with human cancer cells in xenotransplant settings examining susceptibility to TRAIL-induced apoptosis.

Poids moléculaire: ~82kDa as stable trimers (determined by size exclusion chromatography) ~28kDa as monomer (determined by SDS-PAGE)

UniProt: P50591

Pathways: Apoptose, Positive Regulation of Endopeptidase Activity